Menu Search
Equities

vTv Therapeutics Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
5VT0:FRA

vTv Therapeutics Inc

Actions
  • Price (EUR)26.00
  • Today's Change2.00 / 8.33%
  • Shares traded9.00
  • 1 Year change+52.05%
  • Beta0.4698
Data delayed at least 15 minutes, as of Feb 10 2026 07:14 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for metabolic and inflammatory diseases. Its product pipeline includes TTP399, TTP273, HPP737 and HPP593. The lead product candidate, cadisegliatin (TTP399), is an orally administered, small-molecule, liver-selective glucokinase activator (GKA) that is a potential adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). HPP737 is an orally administered, non-central nervous system (non-CNS) penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and offers the potential for an improved tolerability profile and efficacy over commercially available PDE4 inhibitors. TTP273 is an oral, small molecule, glucagon-like peptide 1 (GLP-1) receptor agonist being evaluated for the treatment of type 2 diabetes mellitus. Its product pipeline also includes Azeliragon and HPP3033.

  • Revenue in USD (TTM)17.00k
  • Net income in USD-23.47m
  • Incorporated2015
  • Employees23.00
  • Location
    vTv Therapeutics Inc3980 Premier Dr, Suite 310HIGH POINT 27265United StatesUSA
  • Phone+1 (336) 841-0300
  • Fax+1 (336) 841-0310
  • Websitehttps://vtvtherapeutics.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.